Navigation Links
Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
Date:8/4/2011

BEDMINSTER, N.J., Aug. 4, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Christian S. Schade will join the Company in the newly created position of Executive Vice President and Chief Financial Officer, beginning in early September.  Mr. Schade brings to Omthera, both extensive experience as a public company financial executive in the biopharmaceutical and energy industries, as well as expertise in the public capital markets through his tenure in the investment banking industry.

"As we continue to expand our executive ranks, we are very pleased to welcome Chris to Omthera's management team. With 28 years of public company and capital market transaction experience, Chris' significant expertise will be extremely valuable to us as we continue to pursue our goals, including the completion of our clinical program and commercialization of Epanova™, our novel, Omega-3 free fatty acid product, that is being developed for the treatment of patients with high triglycerides," stated, Jerry Wisler, President and Chief Executive Officer of Omthera.

Since April 2010, Mr. Schade has served as Executive Vice President and Chief Financial Officer at NRG Energy, a NYSE listed, S&P 500 wholesale power generation company based in Princeton, NJ.  While there, he has overseen NRG's corporate financial functions, including Treasury, Accounting, Tax, Risk, Credit Management and Insurance. Prior to joining NRG, he was Senior Vice President Administration and Chief Financial Officer at Medarex Inc., a NASDAQ listed, Princeton-based biopharmaceutical company which was acquired for $2.4 billion by Bristol-Myers Squibb Co. in September 2009.  Mr. Schade played a lead role in negotiations for the sale of Medarex to Bristol-Myers Squibb and helped lead the merger-integration process of the research, development and administrative functions. He also helped Medarex to grow to become a leading pharmaceutical development company, raising capital through a series of public capital market and asset monetization transactions.  While there, in addition to overseeing the manufacturing of multiple development/clinical programs, he also directed the business development team in the pursuit of key licensing agreements and potential acquisition opportunities, and spearheaded the company's investor relations outreach.  

Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London, where he was head of the European Corporate Funding Group and was responsible for certain capital markets activities of Merrill Lynch's European corporate clients.  He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co.  Mr. Schade received an A.B. degree from Princeton University, and received an M.B.A. from the Wharton School at the University of Pennsylvania.  An active member of the community, Mr. Schade currently serves as Chairman of the Board of Trustees of Princeton Academy of the Sacred Heart and coaches boys youth lacrosse. He also serves on the Board of Directors at Integra Life Sciences (IART).

Mr. Schade noted, "I am excited about reentering the health care industry and delighted to join Omthera's management team at this exciting time in the Company's development. I  look forward to utilizing my experiences to assist the Company as it plans ahead for the potential commercialization of an important product; I believe that Epanova has the potential to be a market leader in the large and rapidly growing market for Omega 3 therapeutics. I am very much looking forward to being a part of the team bringing this product to market, with the potential to benefit a large patient population."

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL). Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.
For more information, please visit www.omthera.com.Omthera Contacts:Omthera Media Relations:Douglas Carr

Eric GoldmanFinancial Controller

Rx Communications GroupOmthera Pharmaceuticals

917-322-2563908-741-4323

egoldman@rxir.comDCarr@Omthera.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Christiana Care Health System Rolls Out Electronic Computerized Provider Order Entry
2. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
3. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
4. Christiana Care Health System Leads National Colorectal Cancer Clinical Trial
5. Christiana Care Breast Center First in Delaware to Earn American College of Radiology Accreditation
6. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
7. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
9. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
10. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
11. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
(Date:2/4/2016)... 4, 2016 For hospitals considering enrollment in ... participating in the program, the Health Resources and Services ... the , Mega-Guidance , could have significant impact on ... in September 2016. Essential Insights , ... , summarizes the Mega-Guidance,s key proposed changes, including a ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... and setting the stage for new clinical and scientific initiatives have all marked ... after she was appointed President and CEO of the nation’s oldest cancer center, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... At ... election of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott ... Chairman of the Board,” stated Leslie A. Chambers , APDA President and CEO. ...
(Date:2/5/2016)... ... 2016 , ... In sleep, when the defenses of the day are at ... patients with eating disorders is significant self-criticism, and consequently these patients experience this disease ... as maladaptive means for coping with this unease, but also leads to a reservoir ...
Breaking Medicine News(10 mins):